

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
18 December 2003 (18.12.2003)


PCT

(10) International Publication Number
WO 03/104455 A1

- (51) International Patent Classification⁷: C12N 15/10, C12Q 1/68, G01N 33/50, C12M 1/34
- (21) International Application Number: PCT/GB03/02459
- (22) International Filing Date: 6 June 2003 (06.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/386,391 7 June 2002 (07.06.2002) US
PA 2002 00869 7 June 2002 (07.06.2002) DK
- (71) Applicant (for all designated States except MN, US): SOPHION BIOSCIENCE A/S [DK/DK]; 93 Pederstrupvej, DK-2750 Ballerup (DK).
- (71) Applicant (for MN only): JOHNSTONE, Helen [GB/GB]; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): JESPERSEN, Thomas [DK/DK]; Københavns Universitet, Medicinsk Fysiologisk Institut, Panum Institut, Blegdamsvej 3, DK-2200 København N (DK). BECH, Morten [DK/DK]; Sophion Bioscience A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). KUTCHINSKY, Jonatan [DK/DK]; Sophion Bioscience A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). OLESEN, Søren, Peter [DK/DK]; Emiliekildevej 43, DK-2930 Klampenborg (DK). TABORYSKI, Rafael [DK/DK]; Sophion Bioscience A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK).
- (74) Agent: JOHNSTONE, Helen; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

[Continued on next page]

(54) Title: SCREENING METHODS



(57) Abstract: The present invention relates to screening methods, and in particular, to methods of screening DNA libraries to identify DNA molecules which when expressed in a host cell, give rise to at least one change in the phenotype of the host cell and such phenotype changes being detected using a patch clamp chip construct. Furthermore, the invention concerns the isolation of mRNA, corresponding to the DNA molecule, giving rise to said cellular phenotypic change.

BEST AVAILABLE COPY

WO 03/104455 A1



GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

SCREENING METHODS

The present invention relates to screening methods and, in particular, to methods of screening DNA libraries to identify DNA molecules which, when expressed in a host cell, give rise to at least one change in the phenotype of the host cell.

DNA libraries enable the convenient storage and analysis of polynucleotides, and their transcribed (mRNA) and expressed products (peptides, polypeptides or proteins). The term "DNA library" used herein is intended to embrace a collection of DNA molecules, wherein the individual members of the library encode a different single gene and/or fragment and/or variant thereof. Alternatively, the individual members of the library encode different genes and/or fragments and/or variants thereof.

Screening of DNA libraries conventionally directly investigates the heterologous DNA sequence and/or its expression product with little or no consideration of its effect on cells. Additionally most known methods of DNA library screening are not rapid, high throughput, easy to use techniques.

According to the invention there is provided a method for screening a DNA library comprising;

- (i) providing a substrate for making electrophysiological measurements upon which at least one cell can be arranged;
- (ii) providing at least one cell which expresses at least one heterologous DNA sequence;

(iii) arranging at least one cell on the substrate to permit detection and/or measurement of a change in the electrophysiology of the cell; and

5 (iv) identifying at least one cell of interest which shows at least one phenotypic change.

Screening DNA libraries in the method of this invention allows the close study of nucleotide sequences of known and unknown function, including
10 genes and their expressed peptides, polypeptides and proteins in association with the cellular phenotype.

Preferably, the cell and/or genetic material of interest is isolated to enable further study of the heterologous DNA e.g. by sequencing.

15

Preferably, the results of further studies are maintained on an information carrier. Most preferably, the information carrier is one selected from one or more of the following: paper, email, computer disk and internet page.

20 Preferably, a plurality of cells is provided. Most preferably, each cell contains a different heterologous DNA sequence. Thus, the plurality of cells together comprises a DNA library.

Preferably, screening of a cell population expressing a given DNA library is
25 performed by electrophysiological measurements and/or fluorescence microscopy and/or microscopic analyses of changes in cellular volume and/or shape.

The method of the present invention is used to perform electrophysiological measurements.

5 The principle of studying ion channels in a small membrane area by electrically insulating said patch of membrane under voltage-clamp conditions was outlined by Neher, Sakmann, and Steinback in "The Extracellular Patch Clamp, A Method For Resolving Currents Through Individual Open Channels In Biological Membranes", Pflueger Arch. 375; 219-278, (1978). They found that, by pressing a pipette containing
10 acetylcholine (ACh) against the surface of a muscle cell membrane, they could see discrete jumps in electrical current that were attributable to the opening and closing of ACh-activated ion channels. Their work was limited by the fact that the resistance of the seal between the glass of the pipette and the membrane (10-50 M Ω) was very small relative to the resistance of the
15 channel (10 G Ω). The electrical noise resulting from such a seal is large enough to obscure the currents flowing through ion channels.

It was then discovered that by fire polishing the glass pipettes and by applying suction to the interior of the pipette a seal of very high resistance
20 (1-100 G Ω) could be obtained with the surface of the cell. This Giga-seal reduced the noise by an order of magnitude to levels at which most channels of biological interest can be studied and greatly extended the voltage range over which these studies could be made. This improved seal has been termed a "giga-seal", and the pipette has been termed a "patch pipette". A
25 more detailed description of the giga-seal may be found in O.P. Hamill, A. Marty, E. Neher, B. Sakmann & F.J. Sigworth: Improved patch-clamp techniques for high resolution current recordings from cells and cell-free membrane patches. Pflügers Arch. 391, 85-100, (1981).

Ion channels are transmembrane proteins catalysing transport of inorganic ions across cell membranes. Ion channels are involved in many cellular processes including generating and timing action potentials, synaptic transmission, secretion of hormones, contraction of muscles. Many drugs exert their specific effects via modulation of ion channels. Examples include the antiepileptic compound phenytoin which blocks voltage-dependent Na^+ -channels in the brain and the antihypertensive drug nifedipine which blocks voltage dependent Ca^{2+} -channels in smooth muscle cells. In addition to chemically induced modulation of ion-channel activity, the patch clamp technique has enabled scientists to perform manipulations with voltage dependent channels. These techniques include adjusting the polarity of the electrode in the patch pipette and altering the saline composition to moderate the free ion levels in the bath solution.

Preferably, screening for phenotype changes can further be conducted by studying the effects of the heterologous DNA sequence in conjunction with an applied intra- and/or extra- cellular test agent.

Most preferably, the test agent is at least one selected from one or more of the following: small organic molecules ($\text{MW} < 1000 \text{ g/mol}$), small peptides (less than 100 amino acids), neurotransmitters, hormones and cytokines.

Preferably, the cell containing the heterologous DNA sequence is an animal cell, most preferably selected from Human Embryonic Kidney 293 (HEK 293), Chinese Hamster Ovary (CHO), COS, MDCK, NG108, NIH3T3 or T84.

When an extracellular (e.g. ion concentration, temperature or ligand protein concentration) or intracellular (e.g. ion concentration, protein concentration)

or a heterologous protein) component is altered a change in the cellular conditions may occur. The presence of a recombinant DNA sequence can therefore influence cellular conditions and the measurable phenotype. Predominantly the influence is on the intracellular component wherein the recombinant DNA is expressed thus altering protein concentrations and via the function of some of these proteins, influencing other cellular processes. The influence of the expressed heterologous protein can also extend to effects on extracellular conditions.

An example of the influence of the expressed recombinant protein influencing cellular conditions occurs when the expressed recombinant protein is a cell membrane ion channel. Both the intracellular and extracellular conditions are affected. An ion channel allows and/or causes the movement of ions across cellular membranes. This movement is either extra- to intra-cellular or vice versa and therefore changes the ion concentration both intra- and extra-cellularly.

These changes in cellular conditions are phenotypic changes that can be measured and used to indicate the presence of a genotype of interest i.e. the recombinant DNA encodes a genotype causing a measurable change in the host cell phenotype. The phenotypic changes are measured in comparison to control cells derived from the same cell line as those host cells being transfected, differing in that the control cells are not transfected with a recombinant DNA sequence.

The change in host cell phenotype can be measured using the chip apparatus as described herein, whereby the host cell is subjected to phenotype testing whilst in contact with the substrate of the chip.

Construction of cellular expressed DNA libraries for use in the invention can be performed by standard PCR and cloning techniques in combination with retroviral vector technology. Each member of the DNA library is introduced into host cells such that each cell comprises only one recombinant DNA construct. The presence of two or more heterologous recombinant constructs weakens any potential observable phenotype signal and characterisation of the causal genotype for the observed phenotype is made more difficult. Stable integration of a single recombinant construct in each cell can be achieved by using a low multiplicity of infection (MOI) of the retroviral particles, ensuring a low level of infection of host cells and combined with selection for a resistance gene, contained within the retroviral vector. Preferably the resistance gene used for selection is one from: Neomycin, puromycin, blasticidin D or zeomycin.

Preferred examples of DNA libraries to be studied are cDNA, randomised, polymorphism and genomic libraries.

By "cDNA libraries" we mean DNA libraries obtained by reverse transcription of cellular mRNA.

Advantageously, normalised cDNA libraries are used in order to eliminate a bias from highly expressed genes, and by normalised cDNA libraries we mean cDNA libraries wherein high frequency cDNAs are reduced in frequency producing an approximately equal representation of cDNAs.

By "randomised libraries" we mean DNA libraries of a single polynucleotide wherein each member of the library differs from each other member by one or more nucleotides and said variation has been artificially introduced.

By "polymorphism libraries" we mean DNA libraries of a single polynucleotide wherein each member of the library differs from each other member by one or more nucleotides, wherein said variation is a natural and
5 inherent feature of that polynucleotide.

By "genomic libraries" we mean DNA libraries obtained by the fractionation of whole cellular genomic DNA.

10 DNA libraries can be constructed by several different molecular technologies. Complementary DNA (cDNA) libraries, the most commonly used DNA libraries, are constructed from mRNA isolated from eukaryotic cells. The structure of mRNA incorporates a 3' poly A tail added during post-transcriptional processing, enabling cDNA to be synthesised from the
15 processed mRNA. Isolated mRNA is incubated with an excess of poly T oligonucleotides and reverse transcriptase enzymes, wherein the poly T oligonucleotide anneals to the complementary poly A tail. The reverse transcriptase enzyme is then able to use the poly T oligonucleotide as a primer from which to initiate DNA synthesis whereby the mRNA acts as the
20 template to produce single-stranded DNA for subsequent use as the template for double-stranded cDNA synthesis. The cDNA can be utilised in standard PCR reactions or used for cloning into vectors to create a DNA library [F M Ausubel et al. "Current protocols in Molecular Biology – Volume One" John Wiley & sons, Inc. (1995)].

25 Having been synthesised from mRNA, cDNA differs from genomic DNA in that it does not contain regulatory sequences or introns. The cDNA produced represents the mRNA content of a cell at a particular time, and is unlikely to equally represent every gene from the genome of the parent cell.

Hence, cDNA libraries contain a biased representation of the cellular mRNA, predominantly consisting of housekeeping genes in multiple copies, and low expression genes present in few or no copies. Furthermore, there are unexpressed genes that will not be among the cDNAs produced.

5

It is possible, through a normalisation procedure to create cDNA libraries with a more equal representation of cellular mRNAs [M B Soares *et al.* "Construction and characterisation of a normalised cDNA library", PNAS 91 pp.9228-32 (1994)]. This procedure is performed by using the
10 complementary single-stranded cDNA as an annealing partner and subsequent selection of free single-stranded cDNA. This methodology ensures that high frequency cDNAs are predominantly associated with the complementary strand and considerably reduced in frequency, while normally low frequency cDNAs are only moderately reduced. Selection in
15 this manner can be repeated to produce an approximately equal representation of cDNAs.

A further DNA library, is a genomic DNA library constructed by the direct fractionisation of cellular genomic DNA and insertion of the resulting
20 fragments into an appropriate vector. Such libraries contain DNA with non-coding regions intact. Typically, the fractionation of genomic DNA is achieved by mechanical or enzymatic means.

A further type of DNA library is a randomised library, wherein the library
25 contains clones encoding a single gene, each clone containing a different modification of one or more nucleotides, typically but not exclusively corresponding to the same specific peptide domain of the protein under investigation. Such randomised libraries may be constructed using PCR technology [T Ohmichi *et al.* "Efficient bacterial transcription of DNA

nanocircle vectors with optimised single-stranded promoters”, PNAS 99 pp.54-59 (2002); T Jespersen *et al.* “Efficient non-PCR mediated overlap extension of PCR fragments by exonuclease “end-polishing”, Biotechniques 23 pp.48-52 (1997)]. The randomised modification(s) are introduced into
5 the target nucleotide via PCR primers incorporating the randomised nucleotide sequence(s), thus targeting the modification(s) to specific amino acid positions.

A yet further type of DNA library is a polymorphic library. Many genes
10 within the population of a given organism are polymorphic, i.e. natural variants of the same gene encoding a particular protein. For example, Major Histocompatibility Complex (MHC) proteins contain polymorphisms of amino acids within the peptide binding cleft, such that the binding cleft differs, thereby accounting for the variation between individuals in the
15 ability of their MHC proteins to bind specific targets. [P J Bjorkman and P Parham “Structure, function and diversity of class I Major Histocompatibility Complex molecules” Ann. Rev. Biochem. 59 pp. 253-288 (1990)].

20 A polymorphic library therefore comprises each member of the library encoding a different polymorphic copy of a single gene. Such libraries are particularly of benefit for drug screening to study differentiated response patterns and potential side effects associated with particular polymorphic forms of a gene.

25 Methods of introducing the DNA into cells are well known in the art [Sambrook & Russell, “Molecular cloning; A laboratory manual” 3rd edition, Cold Spring Harbor Laboratory Press (2001)] and include electroporation,

liposome mediated transfer, calcium phosphate co-precipitation and microinjection.

Electroporation is achieved by the application of a brief electrical pulse to a solution containing DNA and the cells that are to be transfected [Review -
5 K Shigekawa & W J Dower "Electroporation of eukaryotes and prokaryotes: a general approach to the introduction of macromolecules into cells", Biotechniques 6 pp. 742-751 (1988)]. The electrical pulse causes transient permeabilisation of the cell membrane during which DNA is able
10 to enter the cell cytosol. A fraction of this DNA is subsequently found in the nucleus where transient expression of the introduced genes occurs, typically peaking between 24 and 72 hours after transfection.

Liposome mediated transfer (lipofection) utilises vesicles with artificial
15 lipid membranes resembling natural lipid cell membranes (liposomes), to carry recombinant DNA. The liposome is able to fuse spontaneously to cell membranes, thereby releasing their contents into the cell cytoplasm. [Review - R J Mannino and S Gould-Fogerite, " Liposome mediated gene transfer", Biotechniques, 6 pp. 682-690 (1988)]

20 Calcium Phosphate co-precipitation was shown by F L Braham and A J van der Eb " A new technique for the assay of infectivity of human adenovirus 5 DNA" Virol., 52 pp. 456-467 (1973); to greatly increase gene transfer into host cells. DNA is mixed with a phosphate buffer solution, to which
25 calcium chloride is added. This produces a fine precipitate of calcium phosphate and DNA that is applied to the host cells, and the cells take up the precipitated DNA into their cytosol over several hours.

Recombinant DNA is reliably introduced into host cells by the process of microinjection. This method requires a fine needle to penetrate the cell, and the DNA is injected directly into the cell cytosol [M Capecchi, " High efficiency transformation by direct microinjection into cultured mammalian
5 cells" Cell, 22 pp. 479-488 (1980)]. Microinjection can be performed with computer controlled apparatus that increases the precision and speed of the technique.

The DNA sequence introduced to the target cell is heterologous DNA, by
10 which we mean a DNA sequence that has been introduced to the cell over and above the cell's normal DNA contents, and wherein each heterologous DNA member of the DNA library differs from each other member by one or more nucleotides.

15 Reliable expression of the heterologous DNA sequence is achieved by stable integration of the cloned DNA into the host cell's DNA. This is reliably achieved, for example, using retroviral transduction systems based upon the natural ability of retroviruses to stably integrate their genome into the host cell's DNA [Mann et al. "Construction of a retrovirus packaging
20 mutant and its use to produce helper-free defective retrovirus", Cell 33 pp.153-159 (1983)] {Figure 1}. In such a system the cloned DNA is introduced into the viral genome. Retroviral transduction systems conventionally contain two functional elements, cis-elements and trans-elements. The trans-elements, encode viral packaging proteins; and cis-
25 elements encode other essential viral nucleotide sequences. Cloned DNA is introduced into the host genome such that it is surrounded by cis-elements as recombinant proviral DNA that is unable to produce its own packaging proteins, therefore the proviral DNA is transfected into a packaging cell.

Packaging cells contain the trans-element and produce the viral coats into which the cloned proviral DNA is packaged to produce infectious particles.

5 The infectious particles are released from the host cell and can be harvested for transfecting the target cell culture, in which it stably integrates the viral genome including the cloned DNA contained therein. The cloned DNA can therefore be expressed in the target cell, and the retrovirus is unable to further replicate as the recombinant viral genome lacks the necessary viral genes [Review - J M Coffin "Retroviridae: The viruses and their
10 replication, pp. 1767 – 1845" In : D M Knipe *et al.* (ed.) "Fields virology" Lippencott-Raven publishers (1996)].

Description of the Drawings

15 Specific embodiments of the invention will now be described with reference to the figures described below:

Figure 1 –*Schematic diagram showing construction and cellular expression of a DNA library using retroviral vectors.* The vector contains the
20 heterologous DNA of interest (gene), a resistance marker (neo – neomycin resistance) and an internal ribosome entry site (IRES). The heterologous DNA is flanked by cis- elements, which include the long terminal repeats (LTR). Transcription of this construct produces mRNA containing both the heterologous DNA and the resistance marker. Randomisation of a specific
25 sequence is achieved by PCR followed by overlap extension. Primer #2 contains randomised nucleotides to introduce nucleotide changes at specific places. The fragments obtained from PCR are mixed in overlap extension to obtain a full-length vector for the retroviral vector transduction system. The vector constructs are transfected into packaging cells where transient

expression produces supernatant that when extracted contains virus that can be applied to the target cells.

Figure 2 – *Schematic diagram showing a single target cell positioned in the test site on the chip.* The cell expresses a single genomic construct. Below the cell is a small opening between the test site and well, the cell membrane at this site is perforated or removed for electrophysiological analysis. Other phenotype analyses are shown (dotted lines). Genotype detection is also conducted by extraction of the mRNA via the opening over which the cell membrane is incomplete.

Figure 3 – Schematic diagram of the preferred chip construct. Constructed with:

1. Chip housing.
2. Micro structured unit.
3. Glass/silica membrane on micro structured unit.
4. Cell containing channel/compartment containing extracellular buffer solution and compound.
5. Channel containing intracellular buffer solution and mRNA from cell in whole-cell configuration.
6. Inlet port/pipetting well for introduction of cells and compound.
7. Cell capture site consisting of an orifice in the membrane 3. The orifice is appropriately shaped to enable a gigaseal and whole-cell formation.
8. Cell in suspension.
9. Micropumps.

Figure 4 – *Schematic diagram showing methods of screening cell phenotype.* A cell with a stably integrated vector for expressing cDNA, from which a membrane bound protein is produced (e.g. ion channel).

- 5 Figure 5 – *Schematic diagram showing phenotype investigation of a peptide randomisation DNA library.* Screening for peptide modulator compounds (coding sequence – XXX) interacting with a known membrane protein. Peptides influencing this membrane protein can have their modulatory effects measured.

10

Figure 6 – *Schematic diagram showing phenotype investigation of peptide randomisation of a larger protein – cellular modulators.* A low efficiency modulator has been randomised to increase its binding efficiency of a known membrane protein. X is a randomised construct from the DNA
15 library.

15

Figure 7 – *Schematic diagram showing phenotype investigation of peptide randomisation of a larger protein – receptors – e.g. ScFv.* ScFV binding site randomisation (altered regions indicated by X) can influence the
20 binding affinity, such affinity can then be phenotypically measured.

20

Examples

Example 1 - Description of the preferred embodiment

25

Prophetic example: Construction of a genomic library expressed in a cell line

The aim of this experiment could be to improve the binding of a given ligand to a specific ion channel. This is done by randomising specific amino

acids within the ion channel in which the ligand is known to bind, introducing these randomised gene products into cells and test it in the micro-array system. Examples of micro-array tests are shown in example 3,4,5.

- 5 The ion channel gene is inserted into a bicistronic retroviral vector containing all the retroviral *cis*-elements necessary for transducing target cells as well as an internal ribosome entry site from EMCV followed by a neomycin selection gene (Morgan RA, Couture L, Elroy-Stein O, Ragheb J, Moss B, Anderson WF. Retroviral vectors containing putative internal
- 10 ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. NAR 1992, 20:1293-9). When the ion channel gene is inserted upstream of the IRES element both the ion channel gene and the neo-gene will be found on the same mRNA transcripts arising from this retroviral vector transcription unit. The ion channel gene
- 15 will then be translated by a cap-scanning mechanism while the neo translation will be initiated from the IRES element. Randomisation of four amino acids in the ion channel is performed by a two-step PCR-based method (see figure 1) (Efficient non-PCR-mediated overlap extension of PCR fragments by exonuclease "end polishing".
- 20 Jespersen T, Duch M, Pedersen FS Biotechniques 1997 Jul;23(1):48, 50, 52). In the first step two parallel PCR's, amplifying each end of the transcription unit (retroviral vector), is performed. Primer #2 encodes 12 randomised nucleotides (given rise to 4 amino acids) just after the 3' sequence annealing to the DNA strand. When these randomised nucleotides
- 25 are incorporated in the coding sequence of the ion channel up to 204 different genotypes will be constructed. Primer #2 and #3 are complementary to each other in the 5'end of the primer and sequences introduced by these primers can thereby be used in an overlap extension procedure. PCR should be performed with the following components: 0.5

µM primers (oligonucleotides), 100 ng template/100 µl reaction, 2.5 unit proofreading polymerase enzyme (such as Pfu (Stratagene) or Platinum Taq DNA polymerase High Fidelity (Life Technologies)) with the corresponding buffer and 200 µM dNTP. PCR conditions (15 cycles): 95 °C
5 30 s, 50 °C 15 s, 72 °C 3 min, preceded by 2 minutes at 95 °C and followed by 5 minutes at 72 °C.

The genomic library obtained in the overlap extension procedure is introduced into the target cells through retroviral packaging cells, such as BOSC23 (Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-
10 titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392-6)(Coffin JM (1996) Retroviridae). When the PCR products is transfected (with e.g. lipofectamine (Life Technologies), according to manufactures instructions) into the packaging cell line the DNA will be transcribed into RNA which will be packed into
15 the retroviral particles produced by the packaging cells. 72 hours post transfection media should be filtered (0.5 µm filter) and added directly to the target cells (transduction). 48 hours post-transduction selection (neomycin) media should be added to the cells. After 14 days non-transduced cells will be dead and transduced cells will appear as colonies.
20 The colonies should be mixed (trypsinised) to obtain a population containing the genomic library. This population can now be used either immediately in screening experiments or be stored at -80 degrees.

Example 2 - Chip for Phenotype analysis

25 A suitable chip for patch clamp experiments is described in WO 02/9402. For use in this invention the chip is modified to enable the extraction of mRNA from the cell and is as shown in figure 3.

The chip contains a planar substrate comprising a first surface part and an opposite second surface part, the first surface part having a plurality of sites each of which is adapted to hold an ion channel-containing structure.

- 5 Each site comprises a measuring electrode associated therewith, the substrate carrying one or more reference electrodes, the measuring electrodes and the respective reference electrode or reference electrodes being electrodes capable of generating, when in electrolytic contact with each other and when a potential difference is applied between them, a
10 current between them by delivery of ions by one electrode and receipt of ions by the other electrode.

- Each of the sites is adapted to provide a high electrical resistance seal between an ion channel-containing structure held at the site and a surface
15 part of the site. The seal, when provided, separates a domain defined on one side of the ion channel-containing structure and in electrolytic contact with the measuring electrode from a domain defined on the other side of the ion channel-containing structure and in electrolytic contact with the respective
20 reference electrode. The seal allows a current flowing through ion channels of the ion channel-containing structure between the electrodes to be determined and/or monitored. The electrodes of the invention are integrated with the substrate and having been formed by a wafer processing technology.

- 25 An ion channel-containing structure (e.g. an animal cell) in a solution may be guided towards a site on a substrate either by active or passive means. When the ion channel-containing structure makes contact with the site, e.g. substrate around an electrode, the contact surfaces form a high electrical resistance seal (a giga-seal) at the site, e.g. surrounding the electrode, so that

an electrophysiological property of the ion channels can be measured using the respective electrode. Such electrophysiological property may be current conducted through the part of membrane of the ion channel-containing structure that is encircled by the giga-seal.

5

In the present context, the term "giga-seal" normally indicates a seal of a least 1G ohm, and this is the size of seal normally aimed at as a minimum, but for certain types of measurements where the currents are large, lower values may be sufficient as threshold values.

10

Preferably the whole cell configuration method of patch-clamping is used. This configuration may be obtained by applying, between the measuring electrode associated with each approved site and a reference electrode, a series of second electric potential difference pulses, monitoring a second current flowing between the measuring electrode and the reference electrode, and interrupting the series of second electric potential difference pulses whenever said second current exceeds a predetermined threshold value, thereby rupturing the part of the ion channel-containing structure which is closest to the measuring electrode.

15

Alternatively, the whole-cell configuration may be obtained by subjecting the part of the ion channel-containing structure that is closest to the measuring electrode to interaction with a pore forming substance.

20

It should be noted that in the present context, the term "whole-cell configuration" denotes not only configurations in which a whole cell has been brought in contact with the substrate at a measuring site and has been punctured or, by means of a pore-forming substance, has been opened to electrical contact with the cell interior, but also configurations in which an

excised cell membrane patch has been arranged so that the outer face of the membrane faces "upwardly", towards a test sample to be applied.

As the measuring electrode associated with a site is one of a plurality of electrodes on the substrate, and the ion channel-containing structure is one of many in a solution, it is preferable that a plurality of measuring sites exists on a particular substrate. The plurality of measuring sites enables a plurality of test cells to be analysed simultaneously.

Example 3 - Electrophysiological measurements

Electrophysiological measurements can be performed using a chip construct made of the substrate and used as described above and in figure 3, to perform patch clamp testing by applying voltage changes to the test cell.

A typical measurement comprises adding a specific test sample to a measuring set-up, for which reason each measuring set-up is separated from other measuring set-ups to avoid mixing of test samples and electrical conduction in between said set-ups. Additionally control cells that have not been transformed with a heterologous DNA sequence are tested to provide a comparative phenotype measurement for that cell line.

A number of test cells can be studied at any one time and the electrophysiological measurements made and analysed to indicate which if any, of the test cells exhibit phenotypes different to that of the control cells.

Electrophysiological measurements produced through the application of voltage changes to the test cell, are used to analyse one or more from the following cellular phenotype characteristics: current amplitude (the

maximal current measured during a depolarisation pulse), activation kinetics (the time constants which the current increases during a depolarisation pulse), inactivation kinetics (the time constants which the current decreases during a depolarisation pulse), deactivation kinetics (the time constants which the current decreases after a depolarisation pulse), activation threshold (the voltage potential opening the ion-permeable pores in the cell membrane) and tail current (the current measured after a depolarisation pulse)(Hille B. Ion channels of excitable membranes. 3th edition. 2001. Sinauer Associates, Inc, Sunderland, MA, USA).

Example 4 - Fluorescence based screening

Certain fluorescent probes are known to bind cellular molecules to indicate one or more of a number of cellular parameters including but not limited to pH (e.g. H⁺ specific probes), membrane potential and concentration fluxes of ions (e.g. Ca²⁺ (fura2) and Mg²⁺ (mag-fluo4) specific probes (Molecular Probes, Inc, The Netherlands))(Methods Cell Biol 1989;30:157-92 Bright GR, Fisher GW, Rogowska J, Taylor DL. Fluorescence ratio imaging microscopy)(Inoue S. Progress in video microscopy. Cell Motil Cytoskeleton 1988;10(1-2):13-7

When voltage changes are applied to the test cell situated on the substrate, where fluorescent probes have been additionally added, the fluorescent probe binds to its specific target molecule, if present within the test cell, causing the induction of a fluorescent signal. The fluorescent signal can be quantified by fluorescence microscopy (Methods Cell Biol 1989;30:157-92 Bright GR, Fisher GW, Rogowska J, Taylor DL. Fluorescence ratio imaging microscopy)(Inoue S. Progress in video microscopy. Cell Motil Cytoskeleton 1988;10(1-2):13-7) and thereby translated into a direct

measurement of the intracellular condition being measured such that and the test cell is compared to control cells to identify those test cells exhibiting different phenotypes.

5 ***Example 5 - Size or shape measurements***

Measurement of changes in size or shape of cells expressing the DNA library enables the characterisation of polynucleotides and/or genes and/or peptides and/or polypeptides and/or proteins that have influenced the overall physical conformation of the host cell in comparison to the control cells. The measurements are performed by automatic microscopic detection (Foskett JK. [Ca²⁺]_i modulation of Cl⁻ content controls cell volume in single salivary acinar cells during fluid secretion. Am J Physiol 1990 Dec;259(6 Pt 1):C998-1004)(S Muallem, BX Zhang, PA Loessberg, and RA Star Simultaneous recording of cell volume changes and intracellular pH or Ca²⁺ concentration in single osteosarcoma cells UMR-106-01. J. Biol. Chem. 1992 267: 17658-17664)

20 ***Example 6 - Isolation of mRNA and characterisation of a "hit"***

Cells providing a "positive" result or "hit", are those cells that exhibit an altered phenotype compared to that of untransformed control cells from the same cell line.

25

When a positive cell has been identified, characterisation of the genotype is the next step in the screening of heterologous DNA sequences. Characterisation of the genotype underlying a positive phenotypic signal will be analysed by isolating the mRNA from the positive cell. The mRNA

can be extracted by one or more methods from pipetting, cell lysis and mechanical removal.

Pipetting occurs whereby one of a pipette, syringe, needle or similar tool is inserted into the cell and part of the cytosol is extracted. A preferable method of pipetting is achieved by extraction of cell cytosol through the channel at the cell capture site {Figures 2 & 3} of the test substrate of the chip. Further preferably the removal of mRNA through said channel is achieved by suction exerted by the micropumps (9) or the insertion of one of a pipette, syringe, needle or similar tool into the cell after being passed through said channel.

Lysis is achieved by the addition of a lysis buffer (e.g. 0.2 M NaOH, 1 % SDS) to the chamber containing the cell, thereby breaking the cell membrane apart and releasing the cellular components.

The mechanical method of mRNA extraction is conducted by; scraping the cell out of the chamber using a tool specially designed for removal of the cell from the hole in the array. The process of scraping the cell from the chamber ruptures the cell and releases the cellular contents from which the mRNA is thereafter extracted.

Further characterisation of the polynucleotide, peptide, polypeptide and/or protein influenced by the applied stimulus is performed by RT-PCR (Reverse Transcriptase PCR) characterisation of the mRNA isolated from the test cell.

In order to amplify only the nucleotides of interest, RT-PCR primer design requires prior knowledge of the nucleotide sequences of interest or those

flanking the nucleotides of interest. In this invention the regions flanking the nucleotide of interest are known, as they comprise the regions of the viral vector surrounding the heterologous DNA sequence.

- 5 After mRNA has been isolated from the positive cell, the RT-PCR primers designed to be complementary to the viral regions flanking the nucleotides of interest, are used to undertake a reverse transcription reaction to synthesise a single stranded cDNA. This cDNA is further used as the template in a conventional PCR reaction, the primers for which contain
10 known restriction sites so that the double stranded products from PCR can be easily subcloned into a further vector.

This new vector containing the nucleotides of interest can be used in sequencing reactions and in expression of appropriate products, in order to
15 better characterise the nucleotide of interest and if appropriate its expression products. Further characterisation of the expression products can be achieved by, for example, conventional patch-clamp or fluorescence testing.

Analysis of cellular expressed cDNA libraries on the chip technology
20 enables the screening of a plurality of known and unknown proteins. The parameters employed in a specific screen are adjusted to the protein function that is under investigation, e.g. if the screening is for new voltage-gated ion channels, the screening method will preferably involve electrophysiological parameters.

25

Example 7 – Application of a test agent

The preferred embodiment can further include a step whereby the test cells are exposed to a test agent, which may or may not influence the phenotype

in conjunction with the heterologous DNA sequence. The phenotypes of test cells are compared to control cells that have additionally been exposed to the test agent.

- 5 Preferably the test agent is at least one from: small organic molecules, small peptides, neurotransmitters, hormones and cytokines.

Example 8 – Further applications of the invention

- 10 The primary use of the invention is in screening DNA libraries, the applications of which are numerous. Potential applications of the invention include, but are not limited to identification and/or characterisation and/or synthesis of novel therapeutic compounds and novel drug targets.
- 15 Further applications include the identification and/or characterisation of: molecules involved in or influencing cellular cascade and/or transduction pathways; amino acids of a binding protein involved and/or necessary for binding to a target molecule
- 20 A yet further application of the invention is the screening of randomised and/or polymorphic libraries for identification and/or characterisation of variants of improved and/or reduced function.

Example 9 – Randomised libraries as a starting point

25

Expression of randomised peptides is of major interest both for the potential discovery of new drugs and in the study of the function and interaction patterns of small peptides {Figure 5}.

Protein function and cellular pathways can be modified by certain small peptides by their binding to specific peptide domains within proteins. As such small peptides possess the potential ability to treat disease. Further study of such peptides found in this invention may show an in vivo lack of function. However, from the isolated mRNA and expressed products it is further possible to create a structural model of the peptide from which a synthetic organic compound mimicking the function of the peptide can be created.

Furthermore, a number of small peptides of unknown function have been found both extra- and intra-cellularly in vivo. Expression of randomised peptides will be one method to elucidate the function of such small peptides.

Example 10 - Larger protein randomisation libraries as a starting point

Further randomisation libraries can comprise the randomisation of localised peptide domains within a larger protein {Figures 6 & 7}. Binding proteins contain domain with different functions, i.e. a binding domain and usually an effector domain. A number of such binding proteins are known to bind their targets with a relatively low affinity, and therefore randomisation of the binding domain to increase (e.g. antibodies) or decrease (e.g. reduce side effects) the affinity between the ligand and target proteins produces a desirable library to study.

Example 11 - Polymorphic libraries as a starting point

Many genes present in the human population are polymorphic. Polymorphic libraries are of interest in screening of potential drugs for side effects and

differentiated response pattern. When the polymorphic library is large and/or not all polymorphic sequences are known it may be beneficial to perform screenings by the chip technology for the ease of convenience of studying.

CLAIMS

1. A method for screening a DNA library comprising:

- 5 (i) providing a substrate for making electrophysiological measurements upon which at least one cell can be arranged;
- (ii) providing at least one cell which expresses at least one heterologous DNA sequence;
- 10 (iii) arranging at least one cell on the substrate to permit detection and/or measurement of a change in the electrophysiology of the cell; and
- 15 (iv) identifying at least one cell of interest which shows at least one phenotypic change.

2. A method as claimed in Claim 1 wherein the method comprises the further step of isolating the cell of interest, and/or genetic material

20 therefrom.

3. A method as claimed in Claim 2 wherein the method comprises the further step of isolating mRNA from the cell of interest identified in step (iii).

25

4. A method as claimed in Claim 3 wherein the method further comprises the step of sequencing the genetic material.

5. A method as claimed in Claim 4 wherein the method further comprises the step of storing or recording the sequence information on an information carrier, such as a computer disk.

5 6. A method as claimed in any preceding claim wherein a plurality of cells is provided in step (ii).

7. A method as claimed in any preceding claim wherein a plurality of cells is provided in step (ii), with each cell containing a different
10 heterologous DNA sequence.

8. A method as claimed in Claim 6 or 7 wherein the plurality of cells together comprises a DNA library of heterologous DNA.

15 9. A method as claimed in Claim 8 wherein the DNA library is a cDNA library.

10. A method as claimed in any one of the preceding claims wherein the change in the electrophysiology of the cell is detected and/or measured by
20 patch clamping.

11. A method as claimed in any preceding claim wherein the cell is treated with a test agent before step (iii).

25 12. A method as claimed in Claim 11 wherein the test agent is selected from at least one of the following: small organic molecules, small peptides, neurotransmitters, hormones and cytokines.

13. A method as claimed in any preceding claim wherein the cell is an animal cell.

14. A method as claimed in any preceding claim wherein the animal cell
5 is selected from: Human Embryonic Kidney 293 (HEK293), Chinese Hamster Ovary (CHO), COS, MDCK, NG108, NIH3T3 or T84.

15. A method as claimed in any one of Claims 6 to 14 wherein the cells are arranged at spaced-apart locations in or on the substrate.

10


Figure 1



Figure 2

Figure 3



4/7
Figure 4





Figure 5



Figure 6

Figure 7

INTERNATIONAL SEARCH REPORT

Internat I Application No
PCT/G5 2459

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/10 C12Q1/68 G01N33/50 C12M1/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q G01N C12M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CAB Data, SEQUENCE SEARCH, BIOSIS, EPO-Internal, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02 24862 A (SCHMIDT CHRISTIAN ;CYTION S A (CH)) 28 March 2002 (2002-03-28) page 31, line 18 - line 22 page 36, line 12 - line 14 page 72, line 19 -page 73, line 11; claims 1-10	1-4,6-15
Y	WO 02 04943 A (SQUIBB BRISTOL MYERS CO) 17 January 2002 (2002-01-17) page 23, line 20 -page 24, line 25; claims 91,98-120 page 26, line 15 -page 27, line 4 page 27, line 27 -page 29, line 4 page 29, line 16 - line 20	1-4,6-9, 11-15
Y	WO 99 64582 A (INTROGENE BV) 16 December 1999 (1999-12-16) the whole document	1-4,6-9, 11-15

☒ Further documents are listed in the continuation of box C:

☒ Patent family members are listed in annex:

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

28 October 2003

Date of mailing of the international search report

03/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

Internal Classification No.
PCT/GB 02459

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01 73000 A (MAXYGEN INC ;KEENAN ROBERT J (US); MINSHULL JEREMY (US); STEMMER W) 4 October 2001 (2001-10-04) the whole document ---	1-4,6-9, 11-15
Y	EP 1 143 013 A (WARNER LAMBERT CO) 10 October 2001 (2001-10-10) page 7, line 2 - line 11 page 8, line 33 - line 34 ---	1-4,6-9, 11-15
A	DE 199 50 385 A (MAX PLANCK GESELLSCHAFT) 3 August 2000 (2000-08-03) the whole document ---	
A	WO 97 27212 A (RIGEL PHARMACEUTICALS INC) 31 July 1997 (1997-07-31) the whole document ---	
A	WO 02 29402 A (SOPHION BIOSCIENCE AS) 11 April 2002 (2002-04-11) cited in the application the whole document ---	
A	WO 01 59447 A (REED MARK A ;UNIV YALE (US); KLEMIC JAMES F (US); KLEMIC KATHRYN C) 16 August 2001 (2001-08-16) the whole document ---	
A	WO 01 25769 A (SOPHION BIOSCIENCE AS) 12 April 2001 (2001-04-12) the whole document -----	

INTERNATIONAL SEARCH REPORT

Inte . C Application No.
03/02459

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 5-complete, (6-15)-partially
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(v) PCT - Presentation of information
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/GB 03/02459

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0224862 A	28-03-2002	AU 8747201 A	02-04-2002
		WO 0224862 A2	28-03-2002
		US 2003052002 A1	20-03-2003
		US 2003098248 A1	29-05-2003
		US 2003146091 A1	07-08-2003
		US 2002104757 A1	08-08-2002
		US 2002144905 A1	10-10-2002
WO 0204943 A	17-01-2002	AU 7189801 A	21-01-2002
		CA 2413663 A1	17-01-2002
		EP 1311848 A2	21-05-2003
		WO 0204943 A2	17-01-2002
		US 2002053915 A1	09-05-2002
WO 9964582 A	16-12-1999	US 6413776 B1	02-07-2002
		AU 756605 B2	16-01-2003
		AU 4294799 A	30-12-1999
		CA 2301403 A1	16-12-1999
		EP 1022335 A1	26-07-2000
		JP 2002526031 T	20-08-2002
		WO 9964582 A2	16-12-1999
		US 2003027170 A1	06-02-2003
		US 2003170633 A1	11-09-2003
		US 2003059794 A1	27-03-2003
		US 6340595 B1	22-01-2002
WO 0173000 A	04-10-2001	AU 8727301 A	08-10-2001
		EP 1276861 A2	22-01-2003
		WO 0173000 A2	04-10-2001
		US 2001049104 A1	06-12-2001
EP 1143013 A	10-10-2001	EP 1143013 A1	10-10-2001
		BR 0101294 A	06-11-2001
		CA 2342677 A1	03-10-2001
		EP 1143017 A2	10-10-2001
		JP 2001314193 A	13-11-2001
		US 2002034728 A1	21-03-2002
DE 19950385 A	03-08-2000	DE 19950385 A1	03-08-2000
		AU 2799500 A	18-08-2000
		WO 0044894 A1	03-08-2000
		EP 1144618 A1	17-10-2001
		JP 2002535003 T	22-10-2002
WO 9727212 A	31-07-1997	US 6365344 B1	02-04-2002
		AU 1707497 A	20-08-1997
		AU 725716 B2	19-10-2000
		AU 1707897 A	20-08-1997
		CA 2244222 A1	31-07-1997
		DE 69722176 D1	26-06-2003
		DK 877752 T3	15-09-2003
		EP 1295952 A2	26-03-2003
		EP 0877752 A1	18-11-1998
		JP 2000504220 T	11-04-2000
		JP 2001509661 T	24-07-2001
		WO 9727212 A1	31-07-1997
		WO 9727213 A1	31-07-1997
		US 6455247 B1	24-09-2002

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/GB 03/02459

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9727212 A		US 6153380 A	28-11-2000
		US 2002127564 A1	12-09-2002
		US 2002146710 A1	10-10-2002
		US 2003104384 A1	05-06-2003
		US 2003044767 A1	06-03-2003
WO 0229402 A	11-04-2002	AU 9367601 A	15-04-2002
		CA 2424498 A1	11-04-2002
		WO 0229402 A2	11-04-2002
		EP 1322955 A2	02-07-2003
		US 2002063067 A1	30-05-2002
WO 0159447 A	16-08-2001	AU 3499601 A	20-08-2001
		EP 1257816 A1	20-11-2002
		WO 0159447 A1	16-08-2001
		US 2002064841 A1	30-05-2002
WO 0125769 A	12-04-2001	AU 7406500 A	10-05-2001
		CA 2385482 A1	12-04-2001
		CN 1377464 T	30-10-2002
		WO 0125769 A2	12-04-2001
		EP 1221046 A2	10-07-2002
		JP 2003511668 T	25-03-2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.